# Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin

> **NCT00162812** · PHASE2 · TERMINATED · sponsor: **Jules Bordet Institute** · enrollment: 338 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Epirubicin

## Key facts

- **NCT ID:** NCT00162812
- **Lead sponsor:** Jules Bordet Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-01
- **Primary completion:** 2008-12
- **Final completion:** 2009-04
- **Target enrollment:** 338 (ESTIMATED)
- **Why stopped:** Low accrual rate
- **Last updated:** 2008-07-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00162812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00162812, "Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00162812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*